PTEN Hamartoma Tumor Syndrome clinical trials at University of California Health
1 research study open to eligible people
open to eligible people ages 18 months and up
The purpose of this study is to determine cross-sectional and longitudinal medical, behavioral, and cognitive differences between PTEN ASD and other groups, as well as to identify cognitive, neural systems, and molecular biomarkers specific to PTEN ASD. In addition, this study will be creating and maintaining a biorepository and linked phenotypic database for PTEN ASD.
Our lead scientists for PTEN Hamartoma Tumor Syndrome research studies include Julian Martinez, MD, PhD.